Cargando…

Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype

BACKGROUND: Targeted therapy in adenocarcinoma is recommended. The use of immune check point inhibitors for the treatment of Non-small cell lung carcinoma (NSCLC) is used as both first-line and the second-line treatment strategy. The current study was undertaken to assess the frequency of programmed...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Rahul Kumar, Shukla, Saumya, Husain, Nuzhat, Islam, Mohammad Hayatul, Hadi, Rahat, Tripathi, Surya Kant, Singhal, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258661/
https://www.ncbi.nlm.nih.gov/pubmed/35092381
http://dx.doi.org/10.31557/APJCP.2022.23.1.131
_version_ 1784741596546203648
author Pandey, Rahul Kumar
Shukla, Saumya
Husain, Nuzhat
Islam, Mohammad Hayatul
Hadi, Rahat
Tripathi, Surya Kant
Singhal, Ashish
author_facet Pandey, Rahul Kumar
Shukla, Saumya
Husain, Nuzhat
Islam, Mohammad Hayatul
Hadi, Rahat
Tripathi, Surya Kant
Singhal, Ashish
author_sort Pandey, Rahul Kumar
collection PubMed
description BACKGROUND: Targeted therapy in adenocarcinoma is recommended. The use of immune check point inhibitors for the treatment of Non-small cell lung carcinoma (NSCLC) is used as both first-line and the second-line treatment strategy. The current study was undertaken to assess the frequency of programmed cell death ligand-1 (PD-L1) expression with anaplastic lymphoma kinase (ALK), proto-oncogene 1, receptor tyrosine kinase (ROS), epidermal growth factor receptor (EGFR), Kirsten rat sarcoma (KRAS), and v-Raf murine sarcoma viral oncogene homolog B (BRAF)V600E driver gene mutations in NSCLC adenocarcinoma phenotype. It assesses the frequencies of all markers in the cases where both treatment strategies can be implemented. Expression of the all markers was further compared with demographic, clinical parameters, and overall survival rate. MATERIALS AND METHODS: The formalin-fixed paraffin-embedded (FFPE) tissue blocks were used in immunohistochemistry (IHC) staining and real-time polymerase chain reaction (RT-PCR) for determining the driver genes and PD-L1 expression in the 100 NSCLC-Adenocarcinoma cases. RESULTS: PD-L1 positivity was observed in 26.36% (n=29/110) cases in adenocarcinoma. No significant differences in PD-L1 expression were observed among patients harboring ALK, ROS1, EGFR, KRAS, and BRAF mutations EGFR mutations had significant association with smoking status. (p= 0.008), Thyroid transcription factor 1 (TTF1) (p=0.0005) and Napsin (p=0.002) expression. ALK gene re-arrangement was significantly related to age (p= 0.001), gender (p= 0.009) and smoking status (p= 0.043). The single versus multiple driver mutations were significantly correlated with smoking status (p=0.005). In the survival rate analysis, EGFR (p=0.058), KRAS (p=0.021), and PD-L1 (p=0.039) were significantly high with the positive versus negative group. CONCLUSIONS: The current study is a novel attempt to document the co-expression of multiple driver mutations in the NSCLC-adenocarcinoma phenotype. PD-L1 immunopositivity in NSCLC-adenocarcinoma was higher with EGFR mutation as compared to those of KRAS, ALK, ROS, and BRAF driver genes.
format Online
Article
Text
id pubmed-9258661
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-92586612022-07-06 Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype Pandey, Rahul Kumar Shukla, Saumya Husain, Nuzhat Islam, Mohammad Hayatul Hadi, Rahat Tripathi, Surya Kant Singhal, Ashish Asian Pac J Cancer Prev Research Article BACKGROUND: Targeted therapy in adenocarcinoma is recommended. The use of immune check point inhibitors for the treatment of Non-small cell lung carcinoma (NSCLC) is used as both first-line and the second-line treatment strategy. The current study was undertaken to assess the frequency of programmed cell death ligand-1 (PD-L1) expression with anaplastic lymphoma kinase (ALK), proto-oncogene 1, receptor tyrosine kinase (ROS), epidermal growth factor receptor (EGFR), Kirsten rat sarcoma (KRAS), and v-Raf murine sarcoma viral oncogene homolog B (BRAF)V600E driver gene mutations in NSCLC adenocarcinoma phenotype. It assesses the frequencies of all markers in the cases where both treatment strategies can be implemented. Expression of the all markers was further compared with demographic, clinical parameters, and overall survival rate. MATERIALS AND METHODS: The formalin-fixed paraffin-embedded (FFPE) tissue blocks were used in immunohistochemistry (IHC) staining and real-time polymerase chain reaction (RT-PCR) for determining the driver genes and PD-L1 expression in the 100 NSCLC-Adenocarcinoma cases. RESULTS: PD-L1 positivity was observed in 26.36% (n=29/110) cases in adenocarcinoma. No significant differences in PD-L1 expression were observed among patients harboring ALK, ROS1, EGFR, KRAS, and BRAF mutations EGFR mutations had significant association with smoking status. (p= 0.008), Thyroid transcription factor 1 (TTF1) (p=0.0005) and Napsin (p=0.002) expression. ALK gene re-arrangement was significantly related to age (p= 0.001), gender (p= 0.009) and smoking status (p= 0.043). The single versus multiple driver mutations were significantly correlated with smoking status (p=0.005). In the survival rate analysis, EGFR (p=0.058), KRAS (p=0.021), and PD-L1 (p=0.039) were significantly high with the positive versus negative group. CONCLUSIONS: The current study is a novel attempt to document the co-expression of multiple driver mutations in the NSCLC-adenocarcinoma phenotype. PD-L1 immunopositivity in NSCLC-adenocarcinoma was higher with EGFR mutation as compared to those of KRAS, ALK, ROS, and BRAF driver genes. West Asia Organization for Cancer Prevention 2022-01 /pmc/articles/PMC9258661/ /pubmed/35092381 http://dx.doi.org/10.31557/APJCP.2022.23.1.131 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. https://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Research Article
Pandey, Rahul Kumar
Shukla, Saumya
Husain, Nuzhat
Islam, Mohammad Hayatul
Hadi, Rahat
Tripathi, Surya Kant
Singhal, Ashish
Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype
title Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype
title_full Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype
title_fullStr Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype
title_full_unstemmed Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype
title_short Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype
title_sort correlation between programmed death ligand-1 (pd-l1) expression and driver gene mutations in non-small cell lung carcinoma- adenocarcinoma phenotype
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258661/
https://www.ncbi.nlm.nih.gov/pubmed/35092381
http://dx.doi.org/10.31557/APJCP.2022.23.1.131
work_keys_str_mv AT pandeyrahulkumar correlationbetweenprogrammeddeathligand1pdl1expressionanddrivergenemutationsinnonsmallcelllungcarcinomaadenocarcinomaphenotype
AT shuklasaumya correlationbetweenprogrammeddeathligand1pdl1expressionanddrivergenemutationsinnonsmallcelllungcarcinomaadenocarcinomaphenotype
AT husainnuzhat correlationbetweenprogrammeddeathligand1pdl1expressionanddrivergenemutationsinnonsmallcelllungcarcinomaadenocarcinomaphenotype
AT islammohammadhayatul correlationbetweenprogrammeddeathligand1pdl1expressionanddrivergenemutationsinnonsmallcelllungcarcinomaadenocarcinomaphenotype
AT hadirahat correlationbetweenprogrammeddeathligand1pdl1expressionanddrivergenemutationsinnonsmallcelllungcarcinomaadenocarcinomaphenotype
AT tripathisuryakant correlationbetweenprogrammeddeathligand1pdl1expressionanddrivergenemutationsinnonsmallcelllungcarcinomaadenocarcinomaphenotype
AT singhalashish correlationbetweenprogrammeddeathligand1pdl1expressionanddrivergenemutationsinnonsmallcelllungcarcinomaadenocarcinomaphenotype